[V View 2021 Annual Report] The salary of 29 A-share chairman exceeds 10 million yuan, and the top of the list is not Chinese
Sino-Singapore Jingwei, May 5 (Fu Jianqing) Entering May, it means that the annual report season of A-share listed companies has ended.
Most companies in the three A-share markets (Shanghai, Shenzhen, and Beijing) have disclosed their annual reports.
In addition to company performance, future plans, etc., executive compensation also attracts the attention of shareholders.
Flush iFind data shows that among the chairman's remunerations that have disclosed specific figures, 29 are over 10 million yuan, and the number one ranking is as high as 25 million yuan.
Li Xiting, chairman of Mindray Medical, topped the list with a salary of 25.3349 million yuan
According to Sino-Singapore Jingwei, in the 2021 A-share listed company chairman salary ranking, Mindray Medical Chairman Li Xiting ranked first with 25.3349 million yuan, WuXi PharmaTech Chairman Li Ge ranked second with a slight gap of less than 600,000 yuan, Yili ranked second. Pan Gang, chairman of the company, ranked third.
At the same time, the above three executives are also the only chairman of the board with a salary of more than 20 million yuan in 2021.
However, there are not a few chairmen with a salary of more than 10 million yuan, a total of 29, mainly in the pharmaceutical biology, electronics, food and beverage industries.
It is worth noting that, as a newcomer to the exchange, the Beijing Stock Exchange has not yet had a chairman whose salary exceeds 10 million yuan, but He Xueqin, the chairman of Beitri, ranked first in the Beijing Stock Exchange with 7.65 million yuan, surpassing the second place by more than 5 million yuan.
The high salary of the chairman usually stems from the company's excellent performance. Many listed companies in the above-mentioned list will have a net profit of several billions or even tens of billions in 2021.
However, there are also a number of companies that have "special" circumstances.
Among the 29 listed companies owned by the chairman with an annual salary of 10 million, 6 will have a net loss in 2021.
Specifically: Songdu has a net loss of 394 million yuan, a year-on-year decrease of 211.90%. The company said that it was mainly due to the provision for asset impairment of self-owned projects and the decline in the gross profit rate of newly delivered projects; Dizhe Pharmaceuticals had a net loss of 670 million yuan. It is said that the main reason is that the company continues to invest funds to launch new products into preclinical research and clinical trials; Tianbang shares have a net loss of 4.462 billion yuan, and the company said that the main reason is that the market price of live pigs has dropped significantly year-on-year; BeiGene has a net loss of 9.748 billion yuan. The company said that the main reason is that most of the product pipelines are still in the stage of new drug research and development; Zhongnan Construction has a net loss of 3.382 billion yuan; Dima shares have a net loss of 2.054 billion yuan.
Top of the list changed hands
There are many changes in the chairman's ten million salary list in 2021 and 2020.
In 2020, there are a total of 18 listed companies whose chairman salary exceeds 10 million yuan, and 4 of them exceed 20 million yuan.
In 2021, 5 of the above-mentioned 18 chairmen will fall off the list with a salary of less than 10 million yuan, namely Jinke Co., Ltd., Vanke A, Shanghai Jahwa, Rongsheng Development and Ogilvy Medical.
It is worth noting that in 2020, Jiang Sihai, the then chairman of Jinke Co., Ltd., overwhelmed Mindray Medical Chairman Li Xiting with a salary of 25.9345 million yuan to win the top spot that year.
Jinke shares ushered in a "coach change" in early 2021, with Zhou Da, born in 1981, serving as the chairman.
Judging from his resume, Zhou Da belongs to the "Old Jinke" person, and has served as the manager of the chairman's office, the deputy director of the development department, the director of the president's office, the assistant to the chairman of the North China and East China regional companies, and the deputy general manager of the Chongqing regional company. Fuling company General manager, general manager of the company's operation management center and other positions.
In the same year, Jinke's revenue was 112.310 billion yuan, a year-on-year increase of 28.04%; net profit fell by nearly 50% year-on-year.
Regarding the reasons for the decline in the company's performance, Jinke said, firstly, it was mainly affected by the rising cost of land acquisition; secondly, due to the impact of real estate regulation and cash flow, the company made provision for impairment of assets such as inventories that were expected to be impaired. The amount was 2.162 billion yuan, a year-on-year increase of 427%; thirdly, due to the decrease in the income of real estate projects developed by joint ventures and joint ventures, investment income decreased by 509 million yuan compared with 2020, a year-on-year decrease of 39.06%.
Profits fell, and so did the chairman's pay.
Zhou Da's salary in 2021 will be 5.7325 million yuan, less than a quarter of the previous term.
In 2021, the newly appointed chairman of Mindray Medical, Li Xiting's salary will increase slightly compared with 2020. The company's revenue in 2021 is 25.270 billion yuan, a year-on-year increase of 20.18%; net profit is 8.002 billion yuan, a year-on-year increase of 20.19%; Profits doubled by more than 20%.
According to public information, Li Xiting is a Singaporean and graduated from the Department of Physics, University of Science and Technology of China, majoring in cryogenic physics.
From 1976 to 1981, he worked at the Wuhan Institute of Physics and was engaged in physical research. From 1981 to 1984, he worked as a visiting scholar at the French Scientific Research Center. From 1984 to 1987, he worked at the Wuhan Institute of Physics. In 1991, he worked in Shenzhen Anke High-tech Co., Ltd.
He presided over the establishment of Mindray Electronics in 1991, and presided over the establishment of Mindray Co., Ltd. in 1999. Since 1999, he has served as director and general manager of Mindray Medical, director, president and co-CEO of Mindray International, and chairman of the executive board.
The average salary of the chairman of the steel industry is the highest
In terms of industries (excluding the chairman’s salary of 0 and undisclosed), the average salary of the chairman of the steel industry reached 2,315,500 yuan, ranking first in the average salary of all 31 industries at the Shenwan level, non-banking finance, real estate, beauty Nursing, pharmaceutical and biological industries are ranked second to fifth.
The steel industry can take the top spot in the above-mentioned rankings, mainly due to the sharp rise in the average price of steel in 2021, and the overall outstanding performance of listed companies in the industry.
According to the operation of the steel industry previously disclosed by the Ministry of Industry and Information Technology, for the whole year of 2021, the cumulative operating income of key large and medium-sized steel enterprises was 6.93 trillion yuan, a year-on-year increase of 32.7%; the total cumulative profit was 352.4 billion yuan, a year-on-year increase of 59.7%, a record high; The sales profit margin reached 5.08%, an increase of 0.85 percentage points from 2020.
From the perspective of the growth rate of net profit in the steel industry, Baotou Iron and Steel Co., Ltd., Bengang Steel Plates, and Hainan Mining ranked the top three.
The net profit attributable to the parent company of Baotou Iron & Steel Co., Ltd. in 2021 was 2.866 billion yuan, a year-on-year increase of 606.09%; the net profit attributable to the parent company of Bengang Steel in 2021 was 2.501 billion yuan, a year-on-year increase of 550.77%; Hainan Mining's net profit attributable to the parent company in 2021 was 874 million yuan, a year-on-year increase 513.55%.
(Sino-Singapore Jingwei APP)
(The opinions in this article are for reference only and do not constitute investment advice. Investment is risky, and you need to be cautious when entering the market.)
All rights reserved by Sino-Singapore Jingwei. Without written authorization, no unit or individual may reproduce, extract or use in other ways.